- Research article
- Open Access
Structural insights into Escherichia coli polymyxin B resistance protein D with X-ray crystallography and small-angle X-ray scattering
BMC Structural Biologyvolume 14, Article number: 24 (2014)
Polymyxin B resistance protein D (PmrD) plays a key role in the polymyxin B-resistance pathway, as it is the signaling protein that can act as a specific connecter between PmrA/PmrB and PhoP/PhoQ. We conducted structural analysis to characterize Escherichia coli (E. coli) PmrD, which exhibits different features compared with PmrD in other bacteria.
The X-ray crystal structure of E. coli PmrD was determined at a 2.00 Å resolution, revealing novel information such as the unambiguous secondary structures of the protein and the presence of a disulfide bond. Furthermore, various assays such as native gel electrophoresis, surface plasmon resonance (SPR), size-exclusion chromatography, dynamic light scattering (DLS), and small-angle X-ray scattering (SAXS) measurements, were performed to elucidate the structural and functional role of the internal disulfide bond in E. coli PmrD.
The structural characteristics of E. coli PmrD were clearly identified via diverse techniques. The findings help explain the different protective mechanism of E. coli compared to other Gram-negative bacteria.
Various antibiotics have been widely used to inhibit bacterial growth or to kill bacteria. Polymyxin B, isolated from the bacterium Paenibacillus polymyxa, is one of the most potent antibiotics. It binds to lipopolysaccharide (LPS), the major component of the outer membrane of Gram-negative bacteria . Because Gram-negative bacteria display the negatively charged LPS on the surface of the outer membrane, the cationic polymyxin B can interact with phospholipids to make the membrane permeable, resulting in the acceleration of water uptake, membrane disruption, and endotoxin release. It acts as a detergent against most Gram-negative bacteria, with the exception of the Proteus group -.
Gram-negative bacteria have developed different protective mechanisms to counteract the effects of polymyxin B. For instance, Salmonella enterica (S. enterica) possesses a pair of two-component systems (TCSs) that are composed of PmrA/PmrB and PhoP/PhoQ. The TCSs are known to modify the acyl chain group or the phosphate group of LPSs, depending on environmental conditions. There are two types of pathways that activate the PmrA/PmrB system of polymyxin B resistance. The first pathway transpires during the growth of bacteria in the presence of high Fe3+ ion or mild acid pH and does not require PhoP/PhoQ , only the histidine kinase PmrB. The phosphorylation of PmrA by PmrB leads to the transcription of PmrA-activated genes, resulting in the modification of LPS layers. The second pathway includes the PhoQ/PhoP system and PmrD in conditions of low extracytoplasmic Mg2+ ions. PhoP is phosphorylated by the sensor PhoQ protein; phosphorylated PhoP then promotes the transcription of PmrD, a signaling protein that can act as a specific connecter between PmrA/PmrB and PhoP/PhoQ ,. PmrD binds to the N-terminal domain of PmrA to prevent the dephosphorylation of PmrA, followed by the activation of the LPS modification process. However, the PmrD protein of E. coli does not play a role as a post-translational activator; thereby, the LPS modification only occurs via the first pathway in E. coli. It is expected to have different functions and structural characteristics compared with the PmrD protein in other bacteria such as S. enterica and Klebsiella pneumoniae (KP). Because the PmrD protein is affiliated to a new class of proteins that utilize different mechanisms of action for signal integration of bacterial cellular processes than those found in other signaling proteins, the identification of its structure and function is vital for a comprehensive understanding of TCSs systems in bacteria . Therefore, the study of E. coli PmrD has been considered a decisive factor for determining discrepancies among several species -.
In this study, we focus on exploring the structural features of E. coli PmrD. The findings reveal the crystal structure of E. coli PmrD in high resolution, and the structural traits are described in detail. Diverse assays were performed to determine the role of the internal disulfide bond. In addition, the solution structures of wild-type and mutant PmrD were determined using SAXS to obtain structural information in the solution environment.
Preparation of the proteins
The E. coli pmrD gene [UniProt: P37590] was isolated from K-12 genomic DNA and amplified by polymerase chain reaction (PCR) with specific primers. The amplified genes were inserted into the bacterial expression vector pET-15b (Novagen, Germany) containing the TEV protease cleavage site . In addition, the C9A mutant was generated by a point mutation to eliminate the internal disulfide bond of PmrD. The His-tagged wild-type and mutant PmrD were expressed in the E. coli strain BL21(DE3) with Luria-Bertani broth containing 100 μg/L ampicillin, and were grown at 37°C to an OD600 of ~0.6. The expression of soluble PmrD was induced by the addition of 0.1 mM 1-thio-β-D-galactoside (IPTG), and the mixture was incubated in a shaker for 6 h. The cell lysate was treated with lysozyme in 20 mM phosphate buffer (pH 7.4) containing 500 mM NaCl and 2 mM β-mercaptoethanol. After sonication, the lysate was centrifuged at 13,000 rpm at 4°C for the removal of cell debris, and the resulting supernatant was loaded onto a Ni-chelating Sepharose fast-flow column charged with Ni ions (GE Healthcare Life Science, Sweden). The contaminants were washed with a washing buffer containing 20 mM phosphate (pH 7.5), 500 mM NaCl, 45 mM imidazole, and 2 mM β-mercaptoethanol. Wild-type and mutant PmrD were then eluted with washing buffer supplemented with 300 mM imidazole. The wild-type and mutant His-tagged PmrD were digested by adding TEV protease at 20°C for 8 h. To remove the uncleaved His-tagged proteins, the cleaved His-tagged fragments were reloaded for Ni-NTA affinity chromatography, and the target proteins were collected in the flow-through. For further purification, the eluted fractions were concentrated using Ultracel concentrators (Amicon) with a YM-10 membrane and loaded onto a HL Superdex 75 column (GE Healthcare Life Science, Sweden) equilibrated with 20 mM Tris (pH 7.0), 150 mM NaCl, 0.5 mM DTT, and 0.5 mM EDTA. Highly purified wild-type and mutant PmrD were concentrated to approximately 7–15 mg/mL by centrifugation and analyzed by 18% SDS-PAGE. In addition, uncleaved His-tagged wild-type and mutant forms were prepared for SPR measurement. The SeMet-substituted PmrD expressed in E. coli B834 (DE3) was purified via the same methods for native PmrD .
For the binding assay with PmrA, the E. coli pmrA gene [UniProt: P30843] was isolated from K-12 genomic DNA and amplified by PCR with specific primers, and was then inserted into the bacterial expression vector pET-28a (Novagen, Germany) containing the TEV protease cleavage site. The recombinant PmrA was overexpressed in the E. coli strain BL21(DE3) induced by 0.1 mM IPTG at 37°C, and purified as described above. The purity of PmrA was proven via gel electrophoresis.
Protein crystallization and data acquisition
Crystals of PmrD were produced via the hanging-drop vapor-diffusion method at 20°C using 24-well Linbro plates (Hampton Research). The initial crystals were obtained after a period of one week at 20°C in 2.0 M ammonium sulfate and 50 mM sodium acetate (pH 4.6). Triclinic crystals were grown for one week to the maximum dimensions of 0.35 × 0.35 × 0.2 mm3. SeMet-substituted crystals were obtained in the same conditions. The crystals were transferred to a cryo-protectant solution and were flash-frozen in a nitrogen stream at 100 K. X-ray crystallographic diffraction data were collected with an ADSC Quantum 210 charge-coupled device (CCD) camera as the detector from the Beamline 4A of the Pohang Accelerator Laboratory (PAL) in Korea. The data for native PmrD and SeMet-substituted PmrD were collected, integrated, and scaled using HKL2000 software . The data collection and processing statistics are summarized in Additional file 1: Table S1.
Structural determination and refinement
Using the NMR structure of E. coli PmrD [PDB: 2JSO] as the starting model , phasing was performed via molecular replacement using MOLREP  in the CCP4 suite. All model building was achieved with COOT  and refined with REFMAC  and PHENIX software . Water picking was accomplished with PHENIX using default parameters. The refined models were validated with PROCHECK . All figures for the structural model were made in PyMol . The structure-refinement statistics are also summarized in Additional file 1: Table S1.
The coordinate and structure factors for E. coli PmrD have been deposited in the RCSB Protein Data Bank (PDB), accession code 4HN7.
Biochemical assays for the verification of the role of disulfide bridge in PmrD
To investigate the role of the internal disulfide bridge in PmrD, the binding affinities of wild-type and mutant PmrD with PmrA were estimated via native gel electrophoresis. Sample solutions with various ratios of PmrD to PmrA were prepared in 20 μL of reaction buffer (20 mM Tris–HCl, pH 7.8, 5 mM MgCl2, and 100 mM KCl) and incubated at 4°C for 1 h. Samples were loaded onto a 4% native polyacrylamide gel that was pre-run at 12 V/cm for 20 min, and they were analyzed at room temperature at 12 V/cm for 80 min in 1X TBE buffer. In addition, the functional change of PmrD caused by the disruption of the intra-disulfide bond was verified thoroughly using a Biacore T100 biosensor system (GE Healthcare, Sweden). A nickel solution was treated on the NTA sensor chip (GE Healthcare, Sweden), and then the His-tagged wild-type and mutant PmrD were separately immobilized on the chip in the running buffer (10 mM HEPES, 150 mM NaCl, 50 μM EDTA, 0.005% Tween 20, and pH 7.4). PmrA proteins with various concentrations ranging from 0.1 to 5 μM were applied to the PmrD-modified channel under continuous flow of 20 μL/min at 25°C. All SPR signals were assessed by a Biacore T100 response unit. The resulting data were analyzed using BIAevaluation software (v3.0), and the sensorgrams were reconstructed and examined using Origin 8.0.
The average sizes of wild-type and mutant PmrD were determined using size-exclusion chromatography. Based on a high-performance liquid chromatography AKTA system (GE Healthcare Life Science, Sweden), wild-type and mutant PmrD were loaded onto the HL Superdex 75 column (GE Healthcare Life Science, Sweden). The separation was carried out at 4°C at a flow rate of 1 mL/min with 25 mM HEPES (pH 7.0), 150 mM NaCl, and 5% glycerol as the mobile phase, and was monitored at an absorbance of 280 nm. Additionally, DLS is also beneficial to evaluate the size of target molecules. Each sample was prepared in solution containing 25 mM HEPES (pH 7.0), 150 mM NaCl, and 5% glycerol, followed by measurement in triplicate utilizing a Zetasizer Nano Z (Malvern Instruments, Malvern, UK). The average size distributions of the two types of PmrD are represented in Additional file 2: Figure S1.
Determining solution-structure using SAXS
SAXS measurements were performed at the 4C beamline of the PAL. A light source from an in-vacuum undulator 20 (IVU 20: 1.4 m length, 20 mm period) of the Pohang Light Source II (PLS storage II) ring was focused on the sample, utilizing a vertical focusing toroidal mirror coated with rhodium and monochromatized with an Si (III) double crystal monochromator (DCM), giving an X-ray beam of wavelength 1.110 Å. The detector was a Rayonix 2D SX165, a two dimensional (2D) charge-coupled detector (Evanston, IL, USA). The sample-to-detector distance for SAXS was 2.0 m. The scattering angle was calibrated with poly(styrene-b-polyethylene-b-polybutadiene-b-polystyrene) block copolymer standards. The solution sample cell with mica windows was 10 μm thick with a volume of 50 μL, and it had an X-ray beam path length of 0.7 mm. All scattering measurements were conducted in the sample buffer containing 25 mM HEPES (pH 7.0) and 150 mM NaCl at 25°C. Because the scattering pattern was closely correlated with radiation damage, the SAXS data were collected in two successive timeframes of 30 s each, to monitor radiation damage. The absence of changes in the scattering patterns over time was confirmed, indicating that no radiation damage occurred during the scattering measurements. SAXS measurements were performed on protein solutions over the concentration range 1–15 mg/mL to obtain good-quality scattering data without any interference between the protein molecules (i.e., to eliminate any concentration effect). Scattering data were collected for 30 s. Each 2D scattering pattern obtained was circularly averaged from the beam center, normalized to the transmitted X-ray beam intensity, and corrected for scattering arising from the buffer solvent .
SAXS data analysis
The experimental scattering patterns of SAXS were analyzed with a scattering program GNOM  to calculate the pair distance distribution function p(r) curve, expressed as follows:
where q is the magnitude of the scattering vector defined by q = (4π/λ)sinθ, 2θ is the scattering angle, λ is the wavelength of the X-ray beam, and r is the distance between the paired scattering elements in the protein. The radius of gyration from a Guinier plot (R g,G ) can be calculated by fitting the measured scattering data with the Guinier equation , expressed as follows:
The radius of gyration can be computed by a substitute method based on the p(r) curve. From the p(r) function, not only I(0) from the full scattering curve but also the maximum diameter of a given protein (D max ) can be obtained from the distance at which p(r) approaches zero. R g,p(r) is expressed by the following equation:
Structural modeling and comparison among wild-type, mutant PmrD, and the crystal structure
The ab initio model-determination program GASBOR  was used to reconstruct the models of wild-type and mutant E. coli PmrD in solution. The reconstructed models were obtained without imposing any symmetry restrictions, and were averaged using DAMAVER . The atomic coordinates of the crystallographic model of PmrD from the crystal structure [PDB: 4HN7] were converted into the SAXS curve using the CRYSOL program . The SUPCOMB program was used to superpose the crystal structure onto the SAXS models reconstructed from the experimental data .
Results and discussion
Overall crystal structure of E. coli PmrD
Prior to elucidation of the protein structure of E. coli PmrD, its amino acid sequences were compared with those of other species. As shown in Figure 1A, the amino acid sequences are highly conserved and their overall structures are coterminous. However, there are slight differences in the N-terminal (alignment number, approximately 10–18) and C-terminal (alignment number, approximately 83–88) regions. Structural determination was carried out to clarify the discrepancies in PmrD among various species.
The crystal structure of E. coli PmrD was initially solved using the molecular-replacement method with the starting model, the NMR structure of E. coli PmrD [PDB: 2JSO]. According to the electron-density map, 88 residues were generally high quality, whereas the C-terminal region of the data was unclear. With the refinement program (REFMAC, CCP4i suite), the final structure of PmrD was refined at 2.00 Å so that the Rwork and Rfree values between the coordinates and the structure factors were 21.1% and 25.4%, respectively. The crystal structure of E. coli PmrD [PDB: 4HN7] was composed of a C-terminal α-helix and an anti-parallel β-barrel containing six β-strands (Figure 1B). The secondary structures of PmrD were defined via the MOLMOL  program (β1: Trp3-Lys7; β2: Arg16-Asp23; β3: Lys29-Lys35; β4: Leu45-Pro48; β5: Leu53-Ile56; β6: Glu59-Ser71; α-helix: Pro74-Ala84). Four long β-strands (β1, β2, β3, and β6) are located near the α-helix, and two short β-strands (β4 and β5) are situated on the opposite side of the α-helix. In addition, the surface electrostatic potential representations of E. coli PmrD were constructed using the PyMOL visualization program (Figure 2). The findings show many charged regions, including electropositive surfaces (surface1: Lys6, Lys7, Lys29, and Lys41; surface2: Arg16, Lys35, and Lys65; surface3: Met1, Arg58 and Lys60; and surface4: Arg79 and Lys82). Among these electropositive regions, surface1 was charged broadly, and surface2 and surface3 were located near each other. It can be expected that the surface1 or surface2-surface3 regions might interact with the electronegative region of PmrA (the phosphorylation site, Asp51) to inhibit the dephosphorylation of PmrA.
Comparison of the E. coli PmrD crystal structure with other structures
The X-ray crystal structure of E. coli PmrD has numerous similarities to the NMR structure of the proteins, including six β-strands, an anti-parallel β-barrel with the topology of 6-3-2-1-4-5-6, and Greek-key topology. These characteristics also exist in KP-PmrD . However, the PmrD proteins display some distinctions, such as the length of each strand, the definitude of structures, and the electrostatic potentials. In particular, the crystal structure exhibits well-defined secondary structures and one disulfide bond, in contrast to the E. coli NMR structure. The structure shows a disulfide bond between the Cys9 residue in the β1 strand and the Cys81 residue in the α-helix (Figure 3). The difference between our structure and that of the NMR is highlighted by factors such as the presence of several reducing agents, and the presence of the disulfide bond is confirmed by further biochemical experiments. This disulfide bond might contribute to the stabilization and fixation of the α-helix within the overall structure.
In accordance with the results of PDBe Fold (version 2.51) , ten PDB structures were found with Z-scores over 4.0 for the crystal structure of PmrD. Some models with Z-scores over 4.7 that shared a β-barrel structure containing several β-strands were superimposed onto the PmrD structure, as shown in Figure 4. The fold of E. coli PmrD belongs to the OB-fold domain, a conserved domain in bacteria and archaea. The OB-fold proteins with a five-stranded beta barrel structure can bind to nucleotides, proteins, and ions, and also have a special fold-related binding face (the center of β2 and β3), depending on the length and sequence of loops 2 and 4 . The crystal structure of excretory-secretory protein 2 has two intra-disulfide bonds, one of which contributes to the stability of the C-terminal region in the same way as in E. coli PmrD .
Verification of the functional change of mutant PmrD lacking in the intra-disulfide bond
To reveal the role of the disulfide bond in PmrD, C9A-mutated PmrD was generated by point mutation, resulting in the removal of the disulfide bridge. Prior to determining the structural disparity, the alteration of the PmrD function in the TCS, especially binding with PmrA, was validated through native gel electrophoresis and the SPR measurement. Because the lack of interaction between PmrD and PmrA inhibits the second pathway for the activation of the LPS modification process, the functional change of mutant PmrD is highly significant to the investigation of LPS modification in E. coli. For the gel analysis, highly purified PmrD and C9A PmrD were incubated with recombinant E. coli PmrA. As represented in Figure 5A, although the ratio of PmrA to wild-type PmrD was changed from 1 to 3, there was no multimer band in the gel. The higher ratio of wild-type PmrD did not affect the binding of wild-type PmrD with PmrA, in accordance with the previous report that E. coli PmrD did not interact with PmrA . Elimination of the intra-disulfide bond in PmrD showed no distinct differences in the interaction of PmrD and PmrA, suggesting that the internal disulfide bond does not play a major role in binding with PmrA to prevent the dephosphorylation of PmrA (Figure 5B).
The functional change in C9A PmrD was further demonstrated in detail, based on the SPR technique. After the His-tagged wild-type PmrD or mutant PmrD was immobilized onto the NTA chip by a coordinate covalent bond, triplicate injections of PmrA were performed at concentrations of 0.1, 1, 3, and 5 μM. The response signals at equilibrium following the injections were utilized to plot the response versus the PmrA concentrations to obtain the dissociation constant (Kd). In the case of wild-type PmrD, PmrA exhibited a low binding affinity to wild-type PmrD as expected, with resulting difficulty in calculating the Kd value (Figure 6A and 6B). Based on the steady-state method: If Kd is larger than half of the highest concentration in the response-versus-concentrations graph, it cannot be calculated from the data. The same outcome was also observed in the C9A PmrD result, as represented in Figure 6C and 6D. There was no significant interaction between PmrA and mutant PmrD, indicating that the internal disulfide bond does not contribute to the function of PmrD.
Confirmation of the structural variation of C9A PmrD
In the crystal structure of E. coli PmrD, it has been shown that the intra-disulfide bond may influence the maintenance of the overall structure. To judge the structural discrepancy between wild-type and mutant PmrD, specific experiments were conducted, including size-exclusion chromatography and DLS. Wild-type and C9A PmrD passed through the HL Superdex 75 column (GE Healthcare Life Science, Sweden). An analogous facet was observed in the profiles that displayed aggregation (~42 mL), dimer (~70 mL), and monomer (~80 mL) peaks. In particular, the elution volumes of the wild-type and mutant monomers were 82.014 mL and 82.000 mL, respectively, implying that their sizes obtained by size-exclusion chromatography were indistinguishable.
The DLS method is known to offer relatively accurate information on the size distribution profile in solution, and was therefore used to more precisely ascertain the size difference between wild-type and mutant PmrD. Through the triplicate measurements, the average sizes of wild-type and mutant PmrD were calculated as 3.668 ± 0.069 nm and 3.870 ± 0.057 nm, respectively. As exhibited in Additional file 2: Figure S1, the size of mutant PmrD at the maximum peak is larger than that of the wild-type form, and the overall distribution of C9A PmrD tends toward large particle sizes, indicating that the exclusion of the intra-disulfide bond in PmrD induces an increase in the overall size. This suggests that the disulfide bond might play an important role in the stabilization and fixation of the α-helix within PmrD.
Reconstruction and evaluation of the solution structures of PmrD based on SAXS
SAXS is a valuable technique for analyzing the entire shape and size of target molecules in solution, and can provide more accurate size estimation than that achieved by size-exclusion chromatography or DLS. We introduced this method to clarify the structural transition of mutant PmrD lacking the intra-disulfide bond. The scattering patterns for E. coli PmrD were obtained from the 4C beamline at PAL. The measurements were taken at room temperature at 2.0 m from the CCD detector. Additional file 3: Figure S2 represents the SAXS profiles of wild-type and mutant PmrD measured in the sample buffer containing 25 mM HEPES (pH 7.0) and 150 mM NaCl. Additionally, the scattering data were contrasted with the theoretical SAXS profile evaluated from the PmrD crystal structure. All scattering patterns were similar, and the residuals of each scattering pattern displayed no systematic errors (Additional file 4: Figure S3). The Guinier plots and residuals were constructed from the scattering curve (Additional file 5: Figure S4). The radius of gyration (Rg,G) values and the scattering patterns show no dependence on the concentration of the protein, implying that there is no interparticle interaction between the proteins. The plots exhibit linear characteristics in the Guinier q regions (q = 1.3Rg, globular protein) and offer structural information to estimate Rg,G. The calculated Rg,G values of wild-type and mutant PmrD were 14.10 Å and 14.63 Å, respectively. Additionally, C values were calculated by the below equation to demonstrate the availability of data in the range from 0.2-0.3 Å−1.
The S/N ratios were 3.0534 and 2.4870, and the calculated C values were 0.2950 and 0.246137 for wild-type and mutant PmrD, respectively. Therefore, the data range from 0.2 to 0.3 Å−1 is acceptable.
Although the Guinier method is expedient to derive the radius of the target particles, it is influenced by several factors. Compared with the computationally straightforward Guinier function, the pair distance distribution function (p(r)) is comparatively unaffected by various factors such as the residual intermolecular interactions and the formation of aggregation, because it employs the entire scattering curve. Therefore, the maximum particle dimension (Dmax) and the radius of gyration (Rg,p(r)) were derived from the p(r) function displayed in Additional file 6: Figure S5A (Dmax: 43.1 Å, Rg,p(r): 14.04 ± 0.02 for wild-type PmrD; Dmax: 46.0 Å, Rg,p(r): 14.46 ± 0.02 for mutant PmrD). Each qmin and qmax value was also presented (qmin: 0.035, qmax: 0.3317 for wild-type PmrD; qmin: 0.035, qmax: 0.3317 for mutant PmrD). All values from the Guinier plots and pair distance distribution functions are listed in Additional file 7: Table S2. The constructed p(r) functions present single peak patterns, which is characteristic of compact globular particles. The globular shapes of wild-type PmrD and C9A PmrD were also substantiated via the Kratky plots as shown in Additional file 6: Figure S5B. The similarity between Rg,G and Rg,p(r) indicates that the real space structure is precisely estimated from the scattering profile. In addition, the differences in Dmax and Rg,p(r) between wild-type PmrD and C9A PmrD apparently suggest that the intra-disulfide bond in E. coli PmrD functions as a supporting force for the overall structure.
Because the p(r) function is an expression of the scattering profile in real space, it can be used to visualize target molecules. The ab initio SAXS model-independent structural models of wild-type and mutant E. coli PmrD were reconstructed using the GASBOR  and DAMAVER  programs, utilizing the GNOM results as a starting file. Based on specific information within the GNOM file, the GASBOR program established a model via a simulated annealing strategy. The 3D representations of proteins were acquired without assigning any restrictions on the symmetry or anisometry of the molecules. Each SAXS model was predicted 12 times and averaged via DAMAVER. Figure 7 shows the reconstructed solution structures of wild-type and mutant PmrD. Both have similar spherical structures, making it difficult to ascertain structural inequalities with only the figures.
To validate the usefulness of the SAXS models, the SUPCOMB superimposition program was used with template files such as the ab initio SAXS models and the crystal structure of E. coli PmrD. As shown in Figure 8, the superimposition models suggest that the PmrD crystal structure fits well to the ab initio SAXS models of the wild-type and dimer forms. The structural consentaneity between the crystal and modeled structures was substantiated quantitatively by means of normalized spatial discrepancy (NSD). The NSD algorithm facilitates rapid superimposition of structural models and offers useful information about the similarity between the models. It is expressed as the standard deviations for one-dimensional data sets. All NSD values between the crystal structure and the ab initio models were less than 0.6, implying that the reconstructed SAXS models were nearly identical to the crystal structure, and that the mutant PmrD structure was also akin to wild-type PmrD.
In summary, the X-ray crystal structure of E. coli PmrD was determined at 2.00 Å resolution, showing that the structure comprised the C-terminal α-helix and the anti-parallel β-barrel containing six β-strands. Moreover, there is a distinguishing disulfide bond between the Cys9 residue in the β1 strand and the Cys81 residue in the α-helix, unlike for the other structures of PmrD in the crystal structure. Additional experiments offered more detailed characterization of the intra-disulfide bond. Native gel electrophoresis and SPR measurements showed that the removal of the disulfide bridge in PmrD did not influence the innate role of E. coli PmrD. On the other hand, the disruption of the internal bond resulted in increased overall size of PmrD, as demonstrated by size-exclusion chromatography and DLS. This structural alteration was further confirmed via ab initio SAXS modeling. Well-reconstructed SAXS models gave an abundance of information, including overall shapes and sizes.
The Groisman group has recently published new findings on discrepancies in the polymyxin B-resistance pathway among several bacteria . They replaced the E. coli pmrB gene with the Salmonella homolog, resulting in the resistance of E. coli to polymyxin B under PmrD-inducing conditions. This result implies that disparities in the polymyxin B-resistance pathway among bacteria could stem from other factors, such as pmrB, rather than from structural differences between the PmrD proteins. Nevertheless, obvious reasons for the discrepancy have not been investigated; therefore, the structural analysis of PmrD is still significant. Our group has been continuously attempting to resolve the structures of PmrA and PmrB. It is anticipated that this investigation will provide critical insights into the bacterial signal-transduction mechanism.
Availability of supporting data
The data sets supporting the results of this article are included within the article and its additional files.
Polymyxin B resistance protein D
- E. coli :
Surface plasmon resonance
Dynamic light scattering
Small-angle X-ray scattering
- S. enterica :
- KP :
Pohang Accelerator Laboratory
Protein Data Bank
Double crystal monochromator
Normalized spatial discrepancy
Polymerase chain reaction
Cardoso LS, Araujo MI, Goes AM, Pacifico LG, Oliveira RR, Oliveira SC: Polymyxin B as inhibitor of LPS contamination of Schistosoma mansoni recombinant proteins in human cytokine analysis. Microb Cell Fact 2007, 6: 1. 10.1186/1475-2859-6-1
Gunn JS, Lim KB, Krueger J, Kim K, Guo L, Hackett M, Miller SI: PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol Microbiol 1998, 27: 1171–1182. 10.1046/j.1365-2958.1998.00757.x
Gunn JS, Ryan SS, Van Velkinburgh JC, Ernst RK, Miller SI: Genetic and functional analysis of a PmrA-PmrB-regulated locus necessary for lipopolysaccharide modification, antimicrobial peptide resistance, and oral virulence of Salmonella enterica serovar typhimurium. Infect Immun 2000, 68: 6139–6146. 10.1128/IAI.68.11.6139-6146.2000
Zhou Z, Ribeiro AA, Lin S, Cotter RJ, Miller SI, Raetz CR: Lipid A modifications in polymyxin-resistant Salmonella typhimurium: PMRA-dependent 4-amino-4-deoxy-L-arabinose, and phosphoethanolamine incorporation. J Biol Chem 2001, 276: 43111–43121. 10.1074/jbc.M106960200
Wosten MM, Kox LF, Chamnongpol S, Soncini FC, Groisman EA: A signal transduction system that responds to extracellular iron. Cell 2000, 103: 113–125. 10.1016/S0092-8674(00)00092-1
Soncini FC, Groisman EA: Two-component regulatory systems can interact to process multiple environmental signals. J Bacteriol 1996, 178: 6796–6801.
Groisman EA, Kayser J, Soncini FC: Regulation of polymyxin resistance and adaptation to low-Mg2+environments. J Bacteriol 1997, 179: 7040–7045.
Mitrophanov AY, Groisman EA: Signal integration in bacterial two-component regulatory systems. Genes Dev 2008, 22: 2601–2611. 10.1101/gad.1700308
Roland KL, Esther CR, Spitznagel JK: Isolation and characterization of a gene, pmrD, from Salmonella typhimurium that confers resistance to polymyxin when expressed in multiple copies. J Bacteriol 1994, 176: 3589–3597.
Kox LF, Wosten MM, Groisman EA: A small protein that mediates the activation of a two-component system by another two-component system. EMBO J 2000, 19: 1861–1872. 10.1093/emboj/19.8.1861
Kato A, Groisman EA: Connecting two-component regulatory systems by a protein that protects a response regulator from dephosphorylation by its cognate sensor. Genes Dev 2004, 18: 2302–2313. 10.1101/gad.1230804
Jung H, Han S, Kim T, Kim MJ, Ban C: Crystallization and preliminary X-ray analysis of native and selenomethionyl polymyxin resistance protein D from E-coli. Macromol Res 2005, 13: 549–552. 10.1007/BF03218496
Otwinowski Z, Minor W: Processing of X-ray diffraction data collected in oscillation mode. Method Enzymol 1997, 276: 307–326. 10.1016/S0076-6879(97)76066-X
Fu W, Yang F, Kang X, Zhang X, Li Y, Xia B, Jin C: First structure of the polymyxin resistance proteins. Biochem Biophys Res Commun 2007, 361: 1033–1037. 10.1016/j.bbrc.2007.07.144
Vagin A, Teplyakov A: Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr 2010, 66: 22–25. 10.1107/S0907444909042589
Emsley P, Cowtan K: Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004, 60: 2126–2132. 10.1107/S0907444904019158
Vagin AA, Steiner RA, Lebedev AA, Potterton L, McNicholas S, Long F, Murshudov GN: REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. Acta Crystallogr D Biol Crystallogr 2004, 60: 2184–2195. 10.1107/S0907444904023510
Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH: PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 2010, 66: 213–221. 10.1107/S0907444909052925
Laskowski RA, MacArthur MW, Moss DS, Thornton JM: PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993, 26: 283–291. 10.1107/S0021889892009944
DeLano WL: The PyMOL Molecular Graphics System, Version 126.96.36.199. Schrödinger, LLC. , [http://www.pymol.org/citing]
Jin KS, Kim DY, Rho Y, Le VB, Kwon E, Kim KK, Ree M: Solution structures of RseA and its complex with RseB. J Synchrotron Radiat 2008, 15: 219–222. 10.1107/S0909049507066319
Semenyuk AV, Svergun DI: GNOM - a program package for small-angle scattering data processing. J Appl Crystallogr 1991, 24: 537–540. 10.1107/S002188989100081X
Guinier A, Fournet G: Small-angle scattering of X-rays. Wiley, New York; 1995.
Svergun DI, Petoukhov MV, Koch MH: Determination of domain structure of proteins from X-ray solution scattering. Biophys J 2001, 80: 2946–2953. 10.1016/S0006-3495(01)76260-1
Volkov VV, Svergun DI: Uniqueness of ab initio shape determination in small-angle scattering. J Appl Crystallogr 2003, 36: 860–864. 10.1107/S0021889803000268
Svergun D, Barberato C, Koch MHJ: CRYSOL - a program to evaluate x-ray solution scattering of biological macromolecules from atomic coordinates. J Appl Crystallogr 1995, 28: 768–773. 10.1107/S0021889895007047
Kozin MB, Svergun DI: Automated matching of high- and low-resolution structural models. J Appl Crystallogr 2001, 34: 33–41. 10.1107/S0021889800014126
Koradi R, Billeter M, Wuthrich K: MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph 1996, 14: 51–55. 29–32 10.1016/0263-7855(96)00009-4
Luo SC, Lou YC, Cheng HY, Pan YR, Peng HL, Chen C: Solution structure and phospho-PmrA recognition mode of PmrD from Klebsiella pneumoniae. J Struct Biol 2010, 172: 319–330. 10.1016/j.jsb.2010.06.007
Krissinel E, Henrick K: Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr D Biol Crystallogr 2004, 60: 2256–2268. 10.1107/S0907444904026460
Arcus V: OB-fold domains: a snapshot of the evolution of sequence, structure and function. Curr Opin Struct Biol 2002, 12: 794–801. 10.1016/S0959-440X(02)00392-5
Kucera K, Harrison LM, Cappello M, Modis Y: Ancylostoma ceylanicum excretory-secretory protein 2 adopts a netrin-like fold and defines a novel family of nematode proteins. J Mol Biol 2011, 408: 9–17. 10.1016/j.jmb.2011.02.033
Chen HD, Jewett MW, Groisman EA: Ancestral genes can control the ability of horizontally acquired loci to confer new traits. PLoS Genet 2011, 7: e1002184. 10.1371/journal.pgen.1002184
We thank to Mihee Kim for help in obtaining the SAXS data and analyzing the data. This work was supported by the National Research Foundation of Korea (NRF- 2014029297 and NRF-2014029301) and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI12C-1852-020013).
The authors declare that they have no competing interests.
HJ and EJ performed the X-ray crystallography and SAXS analysis. JJ carried out the native gel electrophoresis and SPR experiment. HJ, EJ, JJ, and CB wrote and edited the manuscript. All authors read and approved the final manuscript.
Electronic supplementary material
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.